Novartis’ MabThera biosimilar wins EU nod

Novartis is poised to turn up the pressure on sales of Roche’s monoclonal antibody MabThera/Rituxan after EU regulators approved its cheaper biosimilar version of the mega blockbuster for use ac…
Read the full story: PharmaTimes: News RSS